Concepedia

Mutation-based Prognostication

Mutation-Based Prognostication is a prognostic framework in endocrine tumor research that utilizes specific genetic mutations as predictive biomarkers to stratify patient outcomes, distinguishing it from clinical or histopathological prognostic models by its reliance on molecular alteration profiles.

310

Publications

24.3K

Citations

3.4K

Authors

1K

Institutions

Publications per year

2017–2026

150

Parents

Publications

310

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.5K citations · Full text

, , +17

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

, , +17

BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

Mingzhao Xing, William H. Westra, Ralph P. Tufano et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 994 citations · Full text

, , +15

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel et al. · The Lancet Oncology · 2015 · 613 citations

, , +17

TERT Promoter Mutations and Risk of Recurrence in Meningioma

Felix Sahm, Daniel Schrimpf, Adriana Olar et al. · JNCI Journal of the National Cancer Institute · 2015 · 400 citations · Full text

, , +15

1–5 of 310

Authors

3.4K

  1. EV
    Eric Van Cutsem

    KU Leuven, Belgium

    5 publications · 648 citations

    5

    h-index

  2. DA
    Deepti Aurora-Garg

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    4 publications · 2.7K citations

    4

    h-index

  3. PJ
    Peter J.M. Valk

    Erasmus MC, Netherlands

    4 publications · 680 citations

    4

    h-index

  4. CS
    Charles S. Fuchs

    Dana-Farber Cancer Institute, United States

    4 publications · 484 citations

    4

    h-index

  5. HC
    Hyun Cheol Chung

    Yonsei University, South Korea

    3 publications · 2.6K citations

    3

    h-index

1–5 of 3.4K

Institutions

1K

  1. Inserm

    Paris, France

    13 h-index

    52 publications

    5.7K citations

  2. Ludwig-Maximilians-Universität München

    Munich, Germany

    12 h-index

    47 publications

    6.6K citations

  3. Heidelberg University

    Heidelberg, Germany

    12 h-index

    59 publications

    14.3K citations

  4. The University of Texas MD Anderson Cancer Center

    Houston, United States

    10 h-index

    42 publications

    8.7K citations

  5. University Hospital Heidelberg

    Heidelberg, Germany

    9 h-index

    44 publications

    13.5K citations

  6. Memorial Sloan Kettering Cancer Center

    New York, United States

    9 h-index

    81 publications

    10.3K citations

  7. Peking University

    Beijing, China

    8 h-index

    63 publications

    7K citations

  8. Dana-Farber Cancer Institute

    Boston, United States

    8 h-index

    29 publications

    8.6K citations

1–8 of 1K

Venues

  1. PubMed

    Repository · 20 publications · 852 citations

    14

    h-index

  2. Journal of Clinical Oncology

    15 publications · 3.3K citations

    13

    h-index

  3. Oncotarget

    11 publications · 521 citations

    11

    h-index

  4. British Journal of Cancer

    BJC · 9 publications · 991 citations

    9

    h-index

  5. PLoS ONE

    9 publications · 411 citations

    9

    h-index

1–5